Sinotherapeutics Inc. (SHA:688247)

Market Cap	4.11B -17.8%
Revenue (ttm)	446.57M -12.7%
Net Income	47.48M -62.8%
EPS	0.11 -60.7%
Shares Out	449.00M
PE Ratio	83.27
Forward PE	n/a
Dividend	0.05 (0.55%)
Ex-Dividend Date	n/a

Volume	2,567,592
Average Volume	2,305,108
Open	9.23
Previous Close	9.16
Day's Range	9.15 - 9.38
52-Week Range	8.85 - 13.28
Beta	0.20
RSI	46.34
Earnings Date	Apr 30, 2026

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 312
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688247

Financial Performance

In 2025, Sinotherapeutics's revenue was 446.57 million, a decrease of -12.71% compared to the previous year's 511.62 million. Earnings were 47.48 million, a decrease of -62.82%.